Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis

World Journal of Gastroenterology

Volumn 19, Issue 32, 2013, Pages 5389-5392

  Chung, Sook Hee ^a   Park, Soo Jung ^a   Hong, Sung Pil ^a   Cheon, Jae Hee ^a   Kim, Tae Il ^a   Kim, Won Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adalimumab; Intestinal Beh et's disease; Tumor necrosis factor

Indexed keywords

5 ASA; ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; HYDROCORTISONE; MESALAZINE; PREDNISOLONE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; STEROID;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; EDEMA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; REMISSION; STOMACH ULCER; BEHCET SYNDROME; DRUG COMBINATION; FEMALE; INTESTINAL DISEASES; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; BEHCET SYNDROME; COLONOSCOPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL DISEASES; MALE; MIDDLE AGED; REMISSION INDUCTION; SPONDYLITIS, ANKYLOSING; STEROIDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84883015298     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i32.5389     Document Type: Article

References (16)

1. Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, Tanaka Y. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 2011; 21: 184-191 [PMID: 21052764 DOI: 10.1007/s10165-010-0370-y]
2. Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, Igarashi M, Iizuka BE, Matsuda T, Matsui T, Matsumoto T, Sugita A, Takeno M, Hibi T. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol 2007; 42: 737-745 [PMID: 17876543 DOI: 10.1007/s00535-007-2090-4]
3. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet's disease. J Clin Gastroenterol 2000; 30: 144-154 [PMID: 10730919]
4. Lee JH, Kim TN, Choi ST, Jang BI, Shin KC, Lee SB, Shim YR. Remission of intestinal Behçet's disease treated with antitumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007; 22: 24-27 [PMID: 17427642]
5. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49: 725-728 [PMID: 11600479]
6. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Antitumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001; 120: 995-999 [PMID: 11231954]
7. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003; 46: 118-121 [PMID: 12544532 DOI: 10.1097/01. dcr.0000044733.59705.44]
8. Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, Kim JH, Song JK, Yoo B, Yu CS. Antitumor necrosis factoralpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 2007; 50: 672-676 [PMID: 17216141 DOI: 10.1007/s10350-006-0813-x]
9. Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH. Successful treatment of life-threatening intestinal ulcer in Behçet' s disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 2007; 26: 1383-1385 [PMID; 17039261 DOI: 10.1007/s10067-006-0410-3]
10. Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 2009; 15: 1769-1771 [PMID; 19177427 DOI: 10.1002/ibd.20869]
11. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 2007; 66: 565-566 [PMID; 17124248 DOI: 10.1136/ard.2006.064279]
12. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002; 61 Suppl 2: ii51-ii53 [PMID: 12379622]
13. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341: 1284-1291 [PMID: 10528040 DOI: 10.1056/nejm199910213411707]
14. Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, Iwao Y, Hibi T. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet' s disease. Inflamm Bowel Dis 2008; 14: 1259-1264 [PMID; 18393375 DOI: 10.1002/ibd.20457]
15. Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A. Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol 2011; 31: 165-173 [PMID: 21287227 DOI: 10.1007/ s10792-011-9430-3]
16. Altintaş E, Senli MS, Polat A, Sezgin O. A case of Behçet's disease presenting with massive lower gastrointestinal bleeding. Turk J Gastroenterol 2009; 20: 57-61 [PMID: 19330737]